BioNTech has the cash for oncology, but the proof is still ahead

BioNTech made its name with a COVID-19 vaccine. It is now a cancer company with a falling vaccine business and a large cash balance. The question for investors is whether its oncology bets, led by one bispecific antibody, can turn that cash into approved products before the money is spent.

The technology

The pipeline has three kinds of drug. The first is next-generation immunomodulators. Pumitamig, developed with Bristol Myers Squibb, binds PD-L1 and VEGF-A, and is in seven late-stage trials. Gotistobart targets CTLA-4 in the tumor and is in a phase 3 trial in squamous lung cancer. The second is ADCs: trastuzumab pamirtecan against HER2 and elfetabart drozuntecan against B7-H3, both with Duality Biologics. The third is mRNA cancer immunotherapy, including BNT113 and individualized autogene cevumeran.

BioNTech's stated strategy is to use pumitamig as a backbone and add other agents. Its ESMO preview lists more than ten such combination trials, and the Gilead deal for a pumitamig and Trodelvy trial in breast cancer extends that idea to a partner's drug.

The odds

Evidence for pumitamig is still phase 2. In the ROSETTA Lung-02 interim data from 40 evaluable patients, the confirmed response rate with chemotherapy was 57.1% in non-squamous and 68.4% in squamous lung cancer. Those are response rates, not survival, and the comparison with pembrolizumab plus chemotherapy comes from the phase 3 part now recruiting.

The published base rates suggest caution. In the BIO, Informa and QLS study of 2011 to 2020, 28.9% of programs moved from phase II to phase III, 57.8% from phase III to filing, and 7.9% of programs starting phase I reached approval. BioNTech has had misses of its own in recent weeks: BNT113 missed its first primary endpoint and the colorectal autogene cevumeran trial was stopped. Gotistobart's survival result came from 87 patients in an early first stage.

The money

BioNTech has €16.6 billion in cash and securities, which is large for a company with first-half revenue of €223.7 million. The Q2 report shows an IFRS net loss of €1.35 billion in the first half. Guidance for 2026 is revenue of €1.6 billion to €1.9 billion, adjusted R&D of €2.0 billion to €2.3 billion and adjusted SG&A of €700 million to €800 million. By simple arithmetic, spending guidance exceeds revenue guidance by roughly €0.8 billion to €1.5 billion, before cost of sales and other items. Third-quarter revenue should include €613 million from Bristol Myers.

The company is also buying back up to $1.0 billion of its ADSs through May 2027, and had spent $151.6 million in the second quarter.

The risks

Revenue depends on COVID vaccines, where demand is softer than the company expected. Management is changing: Guido Oelkers replaces Ugur Sahin as CEO by February 1, 2027 at the latest, and chief medical officer Özlem Türeci is leaving to lead a new company. The pipeline leans on one asset, pumitamig, and on one partner, Bristol Myers. And the mRNA franchise, a founding technology for BioNTech, has just had two setbacks.

Our read

BioNTech is well funded, and its research depth is not in doubt. The weak points are execution and concentration. A phase 3 win for pumitamig in lung cancer would change the company's profile. A loss would leave a large cash balance and a shrinking vaccine business. The next dated checks are the ESMO data and third-quarter results on November 3, and later the interim analysis of the gotistobart phase 3 and the primary analysis of the HER2 ADC breast cancer trial in the fourth quarter.